Viva Biotech Holdings (HKG: 1873)
Market Cap | 1.29B |
Revenue (ttm) | 2.14B |
Net Income (ttm) | -341.69K |
Shares Out | 2.14B |
EPS (ttm) | -0.10 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 786,500 |
Open | 0.600 |
Previous Close | 0.620 |
Day's Range | 0.590 - 0.610 |
52-Week Range | 0.410 - 1.410 |
Beta | 1.23 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Nov 29, 2024 |
About Viva Biotech Holdings
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical tec... [Read more]
Financial Performance
In 2023, Viva Biotech Holdings's revenue was 2.16 billion, a decrease of -9.42% compared to the previous year's 2.38 billion. Losses were -116.11 million, -78.03% less than in 2022.
Financial numbers in CNY Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/f/r/press4-2615638.jpg)
Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms
Results Highlights for Interim Results ended 30 June 2024 Revenue reached RMB981.8 million Gross profit amounted to RMB339.1 million Net profit grew by 956.0 YoY to RMB144.2 million Adjusted non-IFRS ...
![](https://cdn.snapi.dev/images/v1/d/t/press18-2346485.jpg)
Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future
HONG KONG , March 28, 2024 /PRNewswire/ -- Highlights of the Annual Results as of December 31, 2023: Revenue reached RMB2,155.6 million Gross profit amounted to RMB738.5 million Adjusted non-IFRS net ...
![](https://cdn.snapi.dev/images/v1/t/y/press4-2164938.jpg)
Viva Biotech Secures Approximately US$ 210 Million Funding
HONG KONG , Nov. 20, 2023 /PRNewswire/ -- On November 20, 2023, Viva Biotech Holdings Group (1873. HK) announced that it completed a funding round, securing approximately US$210 million and bringing i...
![](https://cdn.snapi.dev/images/v1/r/1/press13-2041443.jpg)
Viva Biotech (1873.HK) Announces 2023 Interim Results: Solid Growth in Main Business, Significant Rebound in Profitability
Highlights of the Interim Results as of June 30, 2023: Revenue reached RMB1,142.2 million, representing a year-on-year increase of approximately 3.0% Gross profit amounted to RMB406.0 million, represe...
![](https://cdn.snapi.dev/images/v1/p/r/press5-1979860.jpg)
Viva Biotech's Portfolio Company Riparian Pharmaceuticals Announces Exclusive License Agreement and Research Agreement with Pfizer for Novel Cardiovascular Programs
WATERTOWN, Mass. , July 20, 2023 /PRNewswire/ -- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular dis...
![](https://cdn.snapi.dev/images/v1/p/r/press19-1975462.jpg)
Viva Biotech's Portfolio Company DTx Pharma Reached the Acquisition Agreement with Novartis
DTx Pharma's Fatty Acid Ligand Conjugated Oligonucleotide (FALCON™) platform facilitates extra-hepatic delivery of siRNA therapeutics Acquisition includes DTx-1252 with the potential to deliver a tran...
![](https://cdn.snapi.dev/images/v1/h/j/press6-1936994.jpg)
Viva Biotech Announced Strategic Investors with an Investment of Approximately US$ 210 Million
HONG KONG , June 16, 2023 /PRNewswire/ -- On June 11, 2023, Viva Biotech Holdings Group (1873.HK) announced that Viva Shanghai, the primary entity for Viva Biotech's CRO business, successfully raised ...
![](https://cdn.snapi.dev/images/v1/k/v/press11-1874117.jpg)
Viva Biotech's Recent Conferences & Events Review
HONG KONG , May 5, 2023 /PRNewswire/ -- In April, Viva Biotech was invited to attend 2022 SAPA-China Annual Conference, 88th API China, Drug Discovery Chemistry, American Association for Cancer Resear...
![](https://cdn.snapi.dev/images/v1/p/r/press8-1819508.jpg)
Viva Biotech Announced 2022 Annual Results:
Revenue amounted to RMB2,379.6 million, representing a year-on-year (YoY) increase of 13.1%.
![](https://cdn.snapi.dev/images/v1/p/r/press11-1660195.jpg)
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
JERSEY CITY, N.J. and SHANGHAI , Dec. 2, 2022 /PRNewswire/ -- Focus-X Therapeutics (referred to here as "Focus-X"), a nuclide drug company that was invested in and incubated by Viva Biotech, successfu...
![](https://cdn.snapi.dev/images/v1/p/r/press9-1522911.jpg)
Viva Biotech Announced 2022 Interim Results
Order Backlog Expected to Empower Future Growth with Increasing Long-term Competitive Advantage s Financial Highlights for the 6 months ended June 30, 2022: Revenue amounted to RMB1,108.7 million, rep...
![](https://cdn.snapi.dev/images/v1/p/r/press13-1426892.jpg)
Viva Biotech Successfully Held The 3rd Annual Partnership Summit
SHANGHAI , June 23, 2022 /PRNewswire/ -- June 16th-20th, 2022 (Beijing time), Viva Biotech 2022 Partnership Summit was successfully held. Over 300 attendees joined the Summit, including founders from ...
![](https://cdn.snapi.dev/images/v1/p/r/press7-1283871.jpg)
Joint Fight Against COVID-19, Viva Biotech Contributes to the Production of the Oral COVID-19 Antiviral Medication and Virus Tests
SHANGHAI, March 18, 2022 /PRNewswire/ -- At present, COVID-19 is still in pandemic status around the world. The superposition of Delta and Omicron variants are rampant, resulting in the continuous enh...
![](https://cdn.snapi.dev/images/v1/h/w/biotech22-1003491.jpg)
Viva Biotech Revenues Surge on Move Into Contract Drug Manufacturing
Key Takeaways: Viva Biotech's fivefold jump in first-half revenues and move back to profitability come on the back of its acquisition last year of two contract drug makers
![](https://cdn.snapi.dev/images/v1/p/r/press5-986315.jpg)
Viva Biotech Announced 2021 Interim Results
Revenue Increased by 419.5% YoY, CRO Business Income Increased by 62.5% YoY, O rder B acklog Recorded a Significant Increase of 72% Financial Highlights for the 6 months ended June 30, 2021: Revenue a...
![](https://cdn.snapi.dev/images/v1/p/r/press1-870054.jpg)
Totient, a Viva Biotech Portfolio Company, has been Acquired by AbSci
SHANGHAI, June 15, 2021 /PRNewswire/ -- Viva Biotech (01873.HK) declared today that Totient, one of its portfolio companies, has been acquired by AbSci, a synthetic biology company unlocking the poten...
![](https://cdn.snapi.dev/images/v1/b/c/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6038292fvaccine-bottles-forming-a-dollar-signjpgw700opresize-825957.jpg)
Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse
Genscript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to Genscript's Legend Biotech CAR-T subsidiary. Shanghai Fosun Pharma...
![](https://cdn.snapi.dev/images/v1/p/r/press5-813802.jpg)
Viva Biotech and BioMap Reached a Strategic Collaboration Agreement, To Jointly Accelerate the Early Drug Discovery through AI Technology
SHANGHAI, May 10, 2021 /PRNewswire/ -- Hosted by BioMap and Adock, the first generation of China Biocomputing Conference was successfully launched in Suzhou. The conference is aiming to unite with bio...
![](https://cdn.snapi.dev/images/v1/p/r/press7-746049.jpg)
Viva Biotech Announced 2020 Annual Results
The Group's Revenue Surged by 115.7% YoY Revenue from the CFS B usiness I ncreased S ignificantly by 146.3% YoY Establish One-stop Service Platform for Novel Drug Discovery and Production via Intern...
![](https://cdn.snapi.dev/images/v1/p/r/press15---v1cyxpjxqo.jpg)
Accelerating Innovation, Deepening Integration | Viva Biotech Online Investor Day Review
SHANGHAI, Dec. 13, 2020 /PRNewswire/ -- Viva Biotech's Online Investor Day was successfully hosted on December 8, 2020. The management team conducted an online dialogue with nearly 400 investors, focu...
![](https://cdn.snapi.dev/images/v1/p/r/press15-23.jpg)
Viva Biotech and SYNthesis Enters a Strategic Acquisition Agreement, Accelerating the Development of Global Innovative Drug R & D Service Capabilities
SHANGHAI, Sept. 20, 2020 /PRNewswire/ -- Viva Biotech (Shanghai) Co., Ltd. (hereinafter referred to as "Viva Biotech" or "The Company") entered into the Share Purchase Agreement pursuant to which Viva...